Meanwhile, the patient association Vox Obesity says it has seen a growing number of enquiries from people looking to obtain these treatments on the parallel market, after the authorities recently ruled out reimbursement for Wegovy and Mounjaro for the treatment of obesity. “We’ve noticed that many people are disappointed that reimbursement has not been granted,” says its president, Pascale Brughmans.
She says many patients contact the association to find out how to obtain these treatments outside official channels. Some become targets for fraudsters. “People who post public comments under my video are later approached privately by scammers,” she says.
The FAMHP notes that these medicines are offered for sale on fraudulent websites and social media. Their composition and traceability cannot be guaranteed. Some products may contain a different active substance from the one advertised, have an incorrect dosage or contain no active ingredient at all. Serious adverse effects have also been reported after the use of pens containing insulin instead of semaglutide.
The FAMHP therefore urges patients not to obtain these medicines outside legal channels and reminds them that their use requires a prescription and appropriate medical supervision.
The initial translation of this content was generated by AI. All facts, context, and language have subsequently been verified and validated by a human editorial team.
Read more